Catherine A. Shu - Concepedia

Author

Catherine A. Shu

Columbia University Irving Medical Center ORCID

Also Known As

C. Shu, C.A. Shu, Catherine A Shu, Catherine A. Shu, Catherine Ann Shu, Catherine Shu, Chenglin Shu, Cong-Ke Shu, Julia Rotow, Shu, Catherine A.

292

Publications

Citations

H-Index

Concepts

All Affiliations

Columbia University Irving Medical Center Columbia University Memorial Sloan Kettering Cancer Center Yonsei University Janssen (United States)

About

Catherine A. Shu is an author at Columbia University Irving Medical Center specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	29	1.6K
2	Health Sciences	10	10	364
3	Cell Biology	6	6	213
4	Engineering	1	1	66
5	Genetic Medicine	1	1	14

Catherine A. Shu

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial Catherine A. Shu, Justin F. Gainor, Mark M. Awad, The Lancet Oncology OncologyMetronomic TherapyPathologyBronchial NeoplasmCancer Treatment	2020	621
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study Keunchil Park, Eric B. Haura, Natasha B. Leighl, Journal of Clinical Oncology	2021	597
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers Joshua K. Sabari, Giulia C. Leonardi, Catherine A. Shu, Annals of Oncology	2018	315
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With <i>BRCA</i> Mutations Catherine A. Shu, Malcolm C. Pike, Anjali R. Jotwani, JAMA Oncology	2016	226
PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens Jonas J. Heymann, William A. Bulman, David Swinarski, Cancer Cytopathology	2017	205
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, Cancer Discovery	2023	166
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong, Nature	2024	117
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. Ferdinandos Skoulidis, Kathryn C. Arbour, Matthew D. Hellmann, Journal of Clinical Oncology ImmunologyPathologyFirst-line CppCancer BiologyDoublet Chemotherapy	2019	99
Ovarian clear cell carcinoma, outcomes by stage: The MSK experience Catherine A. Shu, Qin Zhou, Anjali R. Jotwani, Gynecologic Oncology MedicineCancer ManagementPathologyGynecologyOncology	2015	96
Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study Connor J. Kinslow, Michael May, Anjali Saqi, Clinical Lung Cancer MedicinePathologyBronchial NeoplasmPulmonary BlastomaNeuroendocrine Tumors	2019	67

Page 1